Integrated Filing — IndAS



General information about company

Scrip Code 524404
NSE Symbol MARKSANS
MSEI Symbol NOTLISTED
ISIN INE750C01026
Name of company MARKSANS PHARMA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 13-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 23-10-2025
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceutical Formulation
Start date and time of board meeting 13-11-2025   17:40:00
End date and time of board meeting 13-11-2025   18:40:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 72,040.90 1,34,039.80
Other income 2,157.20 2,721.30
Total income 74,198.10 1,36,761.10
2 Expenses
(a) Cost of materials consumed 22,772.00 42,041.40
(b) Purchases of stock-in-trade 10,614.10 27,768.80
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (2,527.00) (12,769.90)
(d) Employee benefit expense 10,380.30 20,218.80
(e) Finance costs 581.50 1,188.00
(f) Depreciation, depletion and amortisation expense 2,691.60 5,001.70
(f) Other Expenses
1 Other Expenses 16,352.20 32,319.10
Total other expenses 16,352.20 32,319.10
Total expenses 60,864.70 1,15,767.90
3 Total profit before exceptional items and tax 13,333.40 20,993.20
4 Exceptional items 0.00 0.00
5 Total profit before tax 13,333.40 20,993.20
6 Tax expense
7 Current tax 3,585.70 5,546.50
8 Deferred tax (166.20) (287.40)
9 Total tax expenses 3,419.50 5,259.10
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 9,913.90 15,734.10
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 9,913.90 15,734.10
17 Other comprehensive income net of taxes 3,646.70 10,299.60
18 Total Comprehensive Income for the period 13,560.60 26,033.70
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 9,825.00 15,656.70
Total profit or loss, attributable to non-controlling interests 88.90 77.40
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 13,361.90 25,723.90
Total comprehensive income for the period attributable to owners of parent non-controlling interests 198.70 309.80
21 Details of equity share capital
Paid-up equity share capital 4,531.60 4,531.60
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 2.17 3.45
Diluted earnings (loss) per share from continuing operations 2.17 3.45
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 2.17 3.45
Diluted earnings (loss) per share from continuing and discontinued operations 2.17 3.45
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) NOTES TO CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2025 1. The consolidated unaudited financial results for the quarter and half year ended 30 September 2025 of Marksans Pharma Limited ('the Company' or 'the holding company') and its subsidiaries (collectively referred as 'the group') were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 13 November 2025. The Statutory Auditors of the Company have carried out limited review on the above results in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation'), as 2. The consolidated unaudited financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ‘Interim Financial Reporting’, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India and in terms of the Regulation. 3. The group operates in one reportable business segment namely 'Pharmaceuticals' as per Ind AS 108 on 'Operating Segments'. 4. Other income (net) includes the following net foreign exchange differences, including forward contracts: Description Quarter ended Half year ended Year Ended 30-Sep-25 30-Jun-25 30-Sep-24 30-Sep-25 30-Sep-24 31-Mar-25 Net gain / (loss) 175.10 (37.73) (122.49) 137.37 (96.38) 194.80 5. During half year ended 30 September 2025, the Board of Directors and Shareholders of the Company have approved the Marksans Employees Stock Option Scheme 2024 (Scheme) for the employees of the Company and its subsidiary companies comprising of equity shares of the Company, not exceeding 2,300,000 equity share of face value of Re 1/- each. Under the said Scheme, the Company has granted 400,000 equity stock options of face value of Re 1/- each on 24 September 2025 to the eligible employees of the group.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 30-09-2025
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 91,615.70
Capital work-in-progress 697.10
Investment property
Goodwill 4,343.30
Other intangible assets 5,437.80
Intangible assets under development 3,975.90
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 0.00
Trade receivables, non-current
Loans, non-current 0.00
Other non-current financial assets 364.60
Total non-current financial assets 364.60
Deferred tax assets (net)
Other non-current assets 2,346.40
Total non-current assets 1,08,780.80
2 Current assets
Inventories 95,517.80
Current financial asset
Current investments 78.30
Trade receivables, current 60,311.10
Cash and cash equivalents 48,161.50
Bank balance other than cash and cash equivalents 18,490.00
Loans, current 0.00
Other current financial assets 402.20
Total current financial assets 1,27,443.10
Current tax assets (net) 2,481.90
Other current assets 9,980.70
Total current assets 2,35,423.50
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 3,44,204.30
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 4,531.60
Other equity 2,64,270.60
Total equity attributable to owners of parent 2,68,802.20
Non controlling interest 2,556.80
Total equity 2,71,359.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities 26,619.10
Total non-current financial liabilities 26,619.10
Provisions, non-current 630.60
Deferred tax liabilities (net) 132.00
Deferred government grants, Non-current
Other non-current liabilities
Total non-current liabilities 27,381.70
Current liabilities
Current financial liabilities
Borrowings, current 2,337.50
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 210.10
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 28,271.40
Total Trade payable 28,481.50
Other current financial liabilities 7,789.70
Total current financial liabilities 38,608.70
Other current liabilities 3,858.80
Provisions, current 153.20
Current tax liabilities (Net) 2,842.90
Deferred government grants, Current
Total current liabilities 45,463.60
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 72,845.30
Total equity and liabilites 3,44,204.30
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2025 01-04-2025
Date of end of reporting period 30-09-2025 30-09-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurements of the net defined benefit liabilities/assets -1000000 -2010000
Total Amount of items that will not be reclassified to profit and loss (10.00) (20.10)
2 Income tax relating to items that will not be reclassified to profit or loss (2.60) (5.10)
3 Amount of items that will be reclassified to profit and loss
1 Foreign Currency Translation Reserve 365410000 1031460000
Total Amount of items that will be reclassified to profit and loss 3,654.10 10,314.60
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 3,646.70 10,299.60



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 30-09-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 20,993.20
Adjustments for reconcile profit (loss)
Adjustments for finance costs 1,188.00
Adjustments for decrease (increase) in inventories (6,381.90)
Adjustments for decrease (increase) in trade receivables, current (3,439.50)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (117.10)
Adjustments for decrease (increase) in other non-current assets 21.50
Adjustments for other financial assets, non-current (7.60)
Adjustments for other financial assets, current (51.00)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (1,223.20)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (906.30)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 5,001.70
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current (6.70)
Adjustments for provisions, non-current 22.40
Adjustments for other financial liabilities, current 233.60
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (1,600.70)
Adjustments for dividend income 0.00
Adjustments for interest income 1,246.60
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 763.90
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (4.70)
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 1,233.20
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (6,521.00)
Net cash flows from (used in) operations 14,472.20
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 6,953.60
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 7,518.60
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 26.20
Purchase of property, plant and equipment 7,318.90
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 1,287.80
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 2,357.20
Net cash flows from (used in) investing activities (3,647.70)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings (29.00)
Payments of lease liabilities 1,549.80
Dividends paid 3,625.30
Interest paid 141.60
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (5,287.70)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (1,416.80)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents (0.30)
Net increase (decrease) in cash and cash equivalents (1,417.10)
Cash and cash equivalents cash flow statement at beginning of period 49,578.60
Cash and cash equivalents cash flow statement at end of period 48,161.50





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 MSKA & Associates Yes 31-07-2027